For adults with
GENERALIZED
MYASTHENIA
GRAVIS (gMG)

 

Discover what’s in reach with RYSTIGGO

Ask your doctor about the first FDA-approved treatment
for both anti-AChR and anti-MuSK antibody positive gMG.

SEE RYSTIGGO RESULTS

AChR=acetylcholine receptor; MuSK=muscle-specific tyrosine kinase.

hero image
hero image
hero image
hero image

Reduces gMG symptoms

 

In a clinical trial, people taking RYSTIGGO saw significant improvements in activities of daily living as measured by MG-ADL.

Targeted gMG treatment

 

RYSTIGGO works by targeting FcRn, which can extend the life of harmful antibodies that can cause gMG.

Administered in minutes

 

Once prepared by a healthcare professional, RYSTIGGO subcutaneous infusions may be completed in about 15 minutes.

Individual results may vary, and not all people will experience improvements.
MG-ADL=Myasthenia Gravis Activities of Daily Living.
FcRn=Neonatal Fc receptor.
Infusion time may vary.

Reduces gMG symptoms

 

In a clinical trial, people taking RYSTIGGO saw significant improvements in activities of daily living as measured by MG-ADL.

Individual results may vary, and not all people will experience improvements.
MG-ADL=Myasthenia Gravis Activities of Daily Living.

Targeted gMG treatment

 

RYSTIGGO works by targeting FcRn, which can extend the life of harmful antibodies that can cause gMG.

FcRn=Neonatal Fc receptor.

Administered in minutes

 

Once prepared by a healthcare professional, RYSTIGGO subcutaneous infusions may be completed in about 15 minutes.

Infusion time may vary.
ONWARD™ personalized support designed to move you forward.

Here for you throughout your treatment

ONWARD™ provides personalized support, including help to understand coverage and financial options, tools to help you track symptoms, and guidance when starting and continuing treatment.